300 related articles for article (PubMed ID: 17332064)
1. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone.
Lazarenko OP; Rzonca SO; Hogue WR; Swain FL; Suva LJ; Lecka-Czernik B
Endocrinology; 2007 Jun; 148(6):2669-80. PubMed ID: 17332064
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
Ali AA; Weinstein RS; Stewart SA; Parfitt AM; Manolagas SC; Jilka RL
Endocrinology; 2005 Mar; 146(3):1226-35. PubMed ID: 15591153
[TBL] [Abstract][Full Text] [Related]
3. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.
Li M; Pan LC; Simmons HA; Li Y; Healy DR; Robinson BS; Ke HZ; Brown TA
Bone; 2006 Oct; 39(4):796-806. PubMed ID: 16759917
[TBL] [Abstract][Full Text] [Related]
4. The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption.
Cho ES; Kim MK; Son YO; Lee KS; Park SM; Lee JC
Mol Cells; 2012 Feb; 33(2):173-81. PubMed ID: 22286232
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.
Sorocéanu MA; Miao D; Bai XY; Su H; Goltzman D; Karaplis AC
J Endocrinol; 2004 Oct; 183(1):203-16. PubMed ID: 15525588
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone decreases bone mass and bone marrow fat.
Harsløf T; Wamberg L; Møller L; Stødkilde-Jørgensen H; Ringgaard S; Pedersen SB; Langdahl BL
J Clin Endocrinol Metab; 2011 May; 96(5):1541-8. PubMed ID: 21367933
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E(2) receptor EP(4)-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation.
Ninomiya T; Hosoya A; Hiraga T; Koide M; Yamaguchi K; Oida H; Arai Y; Sahara N; Nakamura H; Ozawa H
Eur J Pharmacol; 2011 Jan; 650(1):396-402. PubMed ID: 20969852
[TBL] [Abstract][Full Text] [Related]
8. Chronic low dose tumor necrosis factor-α (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts without affecting osteoclasts.
Gilbert LC; Chen H; Lu X; Nanes MS
Bone; 2013 Sep; 56(1):174-83. PubMed ID: 23756233
[TBL] [Abstract][Full Text] [Related]
9. Regulation of selective PPARγ modulators in the differentiation of osteoclasts.
Wu H; Li L; Ma Y; Chen Y; Zhao J; Lu Y; Shen P
J Cell Biochem; 2013 Sep; 114(9):1969-77. PubMed ID: 23494891
[TBL] [Abstract][Full Text] [Related]
10. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss.
Fukunaga T; Zou W; Rohatgi N; Colca JR; Teitelbaum SL
J Bone Miner Res; 2015 Mar; 30(3):481-8. PubMed ID: 25257948
[TBL] [Abstract][Full Text] [Related]
11. Osteoblast-targeted overexpression of PPARγ inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice.
Cho SW; Yang JY; Her SJ; Choi HJ; Jung JY; Sun HJ; An JH; Cho HY; Kim SW; Park KS; Kim SY; Baek WY; Kim JE; Yim M; Shin CS
J Bone Miner Res; 2011 Aug; 26(8):1939-52. PubMed ID: 21351141
[TBL] [Abstract][Full Text] [Related]
12. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
Lazarenko OP; Rzonca SO; Suva LJ; Lecka-Czernik B
Bone; 2006 Jan; 38(1):74-84. PubMed ID: 16137931
[TBL] [Abstract][Full Text] [Related]
13. The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats.
Peng S; Zhang G; Zhang BT; Guo B; He Y; Bakker AJ; Pan X; Zhen W; Hung L; Qin L; Leung WN
Bone; 2013 Jul; 55(1):230-40. PubMed ID: 23486180
[TBL] [Abstract][Full Text] [Related]
14. Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I.
Ackert-Bicknell CL; Shockley KR; Horton LG; Lecka-Czernik B; Churchill GA; Rosen CJ
Endocrinology; 2009 Mar; 150(3):1330-40. PubMed ID: 18948404
[TBL] [Abstract][Full Text] [Related]
15. Positive regulation of osteogenesis by bile acid through FXR.
Cho SW; An JH; Park H; Yang JY; Choi HJ; Kim SW; Park YJ; Kim SY; Yim M; Baek WY; Kim JE; Shin CS
J Bone Miner Res; 2013 Oct; 28(10):2109-21. PubMed ID: 23609136
[TBL] [Abstract][Full Text] [Related]
16. Effects of Osteoglycin (OGN) on treating senile osteoporosis by regulating MSCs.
Chen X; Chen J; Xu D; Zhao S; Song H; Peng Y
BMC Musculoskelet Disord; 2017 Oct; 18(1):423. PubMed ID: 29073887
[TBL] [Abstract][Full Text] [Related]
17. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
18. Bone is a target for the antidiabetic compound rosiglitazone.
Rzonca SO; Suva LJ; Gaddy D; Montague DC; Lecka-Czernik B
Endocrinology; 2004 Jan; 145(1):401-6. PubMed ID: 14500573
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.
Lu N; Sun H; Yu J; Wang X; Liu D; Zhao L; Sun L; Zhao H; Tao B; Liu J
PLoS One; 2015; 10(7):e0132744. PubMed ID: 26177280
[TBL] [Abstract][Full Text] [Related]
20. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.
Sampath TK; Simic P; Sendak R; Draca N; Bowe AE; O'Brien S; Schiavi SC; McPherson JM; Vukicevic S
J Bone Miner Res; 2007 Jun; 22(6):849-59. PubMed ID: 17352644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
